<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00529113</url>
  </required_header>
  <id_info>
    <org_study_id>402-C-0702</org_study_id>
    <nct_id>NCT00529113</nct_id>
  </id_info>
  <brief_title>Study With Gemcitabine and RTA 402 for Patients With Unresectable Pancreatic Cancer</brief_title>
  <official_title>A Randomized Phase I/II Study With Gemcitabine and RTA 402 or Gemcitabine and Placebo for Patients With Unresectable Pancreatic Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Reata Pharmaceuticals, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Reata Pharmaceuticals, Inc.</source>
  <brief_summary>
    <textblock>
      This study assesses the safety and efficacy of RTA 402 in combination with gemcitabine in
      patients with unresectable pancreatic cancer.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Phase I will be conducted to determine the MTD of RTA 402 (administered orally Days 1-21 or
      Days 1-28 of a 28-day cycle) in combination with gemcitabine (1000 m/m2). Gemcitabine will be
      administered as an intravenous infusion on Days 1, 8, and 15 of each 28-day cycle.

      The phase II portion of the study will be randomized, and double-blinded. Phase II will
      utilize the RTA 402 MTD determined in Phase I; Arm 1 will consist of gemcitabine + RTA 402.
      RTA 402 capsules will administered orally Days 1-21 of each 28-day cycle (or Days 1-28 if
      appropriate, based on phase I results); gemcitabine (1000 mg/m2) will be administered as an
      intravenous infusion on Days 1, 8, and 15 of each 28-day cycle in each Arm. Arm 2 will
      consist of gemcitabine + placebo, placebo capsules will be taken orally Days 1-21 of each
      28-day cycle (or Days 1-28 if appropriate, based on phase I results). Both treatment arms are
      4-weeks in length.
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    To pursue other indications
  </why_stopped>
  <start_date>September 2007</start_date>
  <completion_date type="Actual">November 2009</completion_date>
  <primary_completion_date type="Actual">November 2009</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Phase I - To determine the maximum tolerated dose (MTD) of RTA 402 in combination with gemcitabine in patients with locally advanced or metastatic pancreatic cancer.</measure>
    <time_frame>End of trial</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Phase II - To determine if treatment with RTA 402 in combination with gemcitabine can increase the progression-free survival versus gemcitabine plus placebo in patients with unresectable metastatic pancreatic cancer.</measure>
    <time_frame>End of Trial</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Phase I - To document any preliminary antitumor activity of RTA 402 in this patient population.</measure>
    <time_frame>End ofTrial</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase I - To characterize the pharmacokinetics (PK) of RTA 402 in this population.</measure>
    <time_frame>End of Trial</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase II - To determine the overall response rate in patients treated with RTA 402 + gemcitabine and in patients treated with gemcitabine + placebo.</measure>
    <time_frame>End of Trial</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase II - To determine the 1-year survival in this patient population.</measure>
    <time_frame>End of Trial</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase II - To determine the toxicities of these regimens.</measure>
    <time_frame>End of Trial</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase II - To determine the changes in quality of life (Functional Assessment of Chronic Illness Therapy (Fatigue), [FACIT-F]).</measure>
    <time_frame>End of Trial</time_frame>
  </secondary_outcome>
  <number_of_arms>9</number_of_arms>
  <enrollment type="Actual">33</enrollment>
  <condition>Pancreatic Neoplasms</condition>
  <condition>Pancreatic Cancer</condition>
  <arm_group>
    <arm_group_label>Phase 1 Cohort 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Bardoxolone methyl 150 mg/day x 21 days and gemcitabine (1000 mg/m2 by intravenous infusion on Days 1, 9, and 15)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Phase 1 Cohort 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Bardoxolone methyl 300 mg /day for 21 days and gemcitabine (1000 mg/m2 by intravenous infusion on Days 1, 9, and 15)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Phase 1 Cohort 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Bardoxolone methyl 150 mg/day for 28 days and gemcitabine (1000 mg/m2 by intravenous infusion on Days 1, 9, and 15)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Phase 1 Cohort 4</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Bardoxolone methyl 200 mg/day for 28 days and gemcitabine (1000 mg/m2 by intravenous infusion on Days 1, 9, and 15)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Phase 1 Cohort 5</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Bardoxolone methyl 250 mg/day for 28 days and gemcitabine (1000 mg/m2 by intravenous infusion on Days 1, 9, and 15)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Phase 1 Cohort 6</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Bardoxolone methyl 300 mg/day x 28 days and gemcitabine (1000 mg/m2 by intravenous infusion on Days 1, 9, and 15)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Phase 1 Cohort 7</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Bardoxolone methyl 350 mg/day x 28 days and gemcitabine (1000 mg/m2 by intravenous infusion on Days 1, 9, and 15)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Phase 2 Cohort 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Bardoxolone methyl maximum tolerated dose(as determined in the Phase 1 portion of the study)/day x 28 days and gemcitabine (1000 mg/m2 by intravenous infusion on Days 1, 9, and 15)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Phase 2 Cohort 2</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo capsules/day x 28 days and gemcitabine (1000 mg/m2 by intravenous infusion on Days 1, 9, and 15)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bardoxolone methyl</intervention_name>
    <description>Bardoxolone methyl capsules (150 mg/day) for 21 days</description>
    <arm_group_label>Phase 1 Cohort 1</arm_group_label>
    <other_name>RTA 402</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bardoxolone methyl</intervention_name>
    <description>Bardoxolone methyl capsules (300 mg/day) for 21 days</description>
    <arm_group_label>Phase 1 Cohort 2</arm_group_label>
    <other_name>RTA 402</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bardoxolone methyl</intervention_name>
    <description>Bardoxolone methyl capsules (150 mg/day) for 28 days</description>
    <arm_group_label>Phase 1 Cohort 3</arm_group_label>
    <other_name>RTA 402</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bardoxolone methyl</intervention_name>
    <description>Bardoxolone methyl capsules (200 mg/day) for 28 days</description>
    <arm_group_label>Phase 1 Cohort 4</arm_group_label>
    <other_name>RTA 402</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bardoxolone methyl</intervention_name>
    <description>Bardoxolone methyl capsules (250 mg/day) for 28 days</description>
    <arm_group_label>Phase 1 Cohort 5</arm_group_label>
    <other_name>RTA 402</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bardoxolone methyl</intervention_name>
    <description>Bardoxlone methyl capsules (300 mg/day) x 28 days</description>
    <arm_group_label>Phase 1 Cohort 6</arm_group_label>
    <other_name>RTA 402</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bardoxolone methyl</intervention_name>
    <description>Bardoxolone methyl capsules (350 mg/day) x 28 days</description>
    <arm_group_label>Phase 1 Cohort 7</arm_group_label>
    <other_name>RTA 402</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Gemcitabine</intervention_name>
    <description>1,000 mg/m2 administered as an intravenous infusion on days 1, 8, and 15</description>
    <arm_group_label>Phase 1 Cohort 1</arm_group_label>
    <arm_group_label>Phase 1 Cohort 2</arm_group_label>
    <arm_group_label>Phase 1 Cohort 3</arm_group_label>
    <arm_group_label>Phase 1 Cohort 4</arm_group_label>
    <arm_group_label>Phase 1 Cohort 5</arm_group_label>
    <arm_group_label>Phase 1 Cohort 6</arm_group_label>
    <arm_group_label>Phase 1 Cohort 7</arm_group_label>
    <arm_group_label>Phase 2 Cohort 1</arm_group_label>
    <arm_group_label>Phase 2 Cohort 2</arm_group_label>
    <other_name>Gemzar</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo capsules x 28 days</description>
    <arm_group_label>Phase 2 Cohort 2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bardoxolone methyl</intervention_name>
    <description>Bardoxolone methyl maximum tolerated dose (as determined in the Phase 1 portion of the study)/day x 28 days</description>
    <arm_group_label>Phase 2 Cohort 1</arm_group_label>
    <other_name>RTA 402</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Phase I patients should have treatment naïve pancreatic cancer; however , Phase I
             patients who have had 1 prior regimen consisting of adjuvant chemo-radiation or
             adjuvant gemcitabine - as defined within the NCCN guidelines may be enrolled. Phase II
             patients must have metastatic disease (Stage IV only).

          -  Karnofsky performance status of &gt;70%

          -  Adequate liver function. (total bilirubin ≤ 1.5 mg/dL and AST(SGOT) and ALT(SGPT) of &lt;
             2.5 ULN ( ≤ 5 ULN for Phase II patients with liver metastases), Serum Creatinine &lt; 1.5
             ULN

          -  Adequate bone marrow function as documented by the following laboratory test results
             within 14 days of starting therapy. platelets ≥100,000/mm3, absolute neutrophil count
             (ANC) ≥1500/mm3, hemoglobin ≥9.0 g/dL, white blood cell (WBC) count ≥3000 /mm3

          -  Practice effective contraception during the entire study period.

          -  Life expectancy of more than 3 months.

          -  Able and willing to sign the informed consent form.

          -  Willing and able to self-administer orally and document all doses of RTA 402 ingested.

        Exclusion Criteria:

          -  Prior treatment for current malignancy outside of the adjuvant setting for Phase I

          -  Inability to swallow tablets or capsules

          -  Active brain metastases or primary central nervous system (CNS) malignancies.
             (Patients with a previously treated brain metastasis may be included.)

          -  Active second malignancy

          -  Ten percent or greater weight loss over the 6 weeks before study entry.

          -  Pregnant or breast feeding

          -  Clinically significant illnesses which could compromise participation in the study,
             including, but not limited to: Uncontrolled diabetes; Active or uncontrolled
             infection; Acute or chronic liver disease; Confirmed diagnosis of Human
             immunodeficiency virus (HIV) infection; Uncontrolled hypertension, symptomatic
             congestive heart failure, unstable angina pectoris, myocardial infarction within the
             past 6 months, or uncontrolled cardiac arrhythmia.

          -  Psychiatric illness that would limit compliance with study requirements.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Rocky Mountain Cancer Center (US Oncology)</name>
      <address>
        <city>Denver</city>
        <state>Colorado</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cancer Centers of Florida (US Oncology)</name>
      <address>
        <city>Ocoee</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Central Indiana Cancer Centers (US Oncology)</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sammons Cancer Center (US Oncology)</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75246</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Northwest Cancer Specialist- Vancouver Cancer Specialist (US Oncology)</name>
      <address>
        <city>Vancouver</city>
        <state>Washington</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 12, 2007</study_first_submitted>
  <study_first_submitted_qc>September 12, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 14, 2007</study_first_posted>
  <disposition_first_submitted>June 6, 2011</disposition_first_submitted>
  <disposition_first_submitted_qc>June 21, 2011</disposition_first_submitted_qc>
  <disposition_first_posted type="Estimate">June 29, 2011</disposition_first_posted>
  <last_update_submitted>November 13, 2014</last_update_submitted>
  <last_update_submitted_qc>November 13, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 26, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>pancreatic cancer</keyword>
  <keyword>gemcitabine</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pancreatic Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Gemcitabine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted, but a results disposition has been submitted           -->
</clinical_study>

